Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy and safety of 0.5 mg in adult patients with visual impairment due to choridal neovascularization (CNV).


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01840410
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 3
Start date September 2013
Completion date November 2015

See also
  Status Clinical Trial Phase
Terminated NCT00902785 - A Study Of Early Markers Of Choroidal Neovascularization Phase 4
Terminated NCT00327470 - An Open Label Trial to Investigate Macugen for the Preservation of Visual Function in Subjects With Neovascular AMD Phase 4